The Action of Nanomedicine/Nanomaterials for Pulmonic Diseases

Romana Kaiser^*
*Correspondence: Romana Kaiser, Department of Pulmonology, Paracelsus Medical University, Salzburg, Austria, Email:

Editorial

Respiratory conditions include a wide diapason of ails affecting individualities in all age groups from the fetal period to the senior. By increased life expectation, stopgap for a comfortable life for senior becomes especially important, and nanomedicine may help. The lung is a veritably suitable target for medicine delivery due to easy, non-invasive and safe administration via inhalation aerosols. Direct delivery to the point of action for the treatment of lung complaint and injuries, and because of availably of lavage face areas for original medicine action and systemic immersion of medicines.

In this regard, nanomedicine experimenters by considering three introductory principles in this subject, Diagnosis and imaging based on nanotechnology, Targeted drug delivery, Reconstructive surgery respiratory complaint, videlicet were suitable to profit from nanomedicine technology in some habitual pulmonary conditions. Since nanocarrier systems can be fluently transferred to the airways, numerous respiratory conditions has been treated. Pulmonary conditions that have so far been searched for this purpose are a large list, including habitual Obstructive pulmonary complaint, cystic fibrosis and some other inheritable diseases, tuberculosis and contagious conditions, cancer, and pediatric conditions and we're reviewing some of them.

Pulmonary tuberculosis

Some experimental studies have estimated the implicit efficacity of nanoparticles used in antimicrobial treatments. Operation of nanotechnology for treatment of tuberculosis was the subject of primary studies. Pandey and associates in India have reported the effect of direct delivery ofantituberculosis medicines by nanoparticles in several studies. Pandey's group directly enteredanti-tuberculosis medicine nanoparticles fabricated through multiple conflation vacuum- dried system into the lungs of guinea gormandizers by nebulization [1]. One time nebulized administration of medicine kept the medicine position high for 6 to 8 days in the blood sluice and up to 11 days in the lungs. In this system, half- life of the medicine and its bioavailability were advanced compared to its oral administration or injection of medicines [2].

This effect for rifampin, isoniazid and pirazinamid was12.7, 32.8 and 14.7 times, independently. In this trial, by five times operation of Poly (lactide-coglycolide) (PLG) as a carrier in medicine inhalation at 10 days interval the guinea gormandizer come fully free from the TB bacilli. In comparison, by oral administration of medicine, this result could be achieved after 46 times of administration [3]. Bhardwaj and associates in India used a combination of chemotherapeutic agent- loaded vesicular system to overcome TB. They developed ligand added liposome with Dry Powder Inhaler (DPI), using colorful

in vitro and in vivo parameter and reported good result. Several other studies have also estimated the use ofanti-TB nanoparticle medicines delivery. The attained results each mentioned the following advantages [4].

• Shortening the treatment course

• Targeted drug delivery and therapy

• Use of minimum required drug dosages

• Preventing drug side effects

Ventilator- associated pneumonia (VAP), a device related pneumonia which is directly related to the colonization of endotracheal tube (ETT) duringling term mechanical ventilation. The opinion of VAP is delicate because of unspecific radiographic and clinical signs. Machado used nanomodified coatings on ETT handed and effective strategy to help biofilm conformation and ETT colonization. They used selenium and iron oxide nanoparticles to access into biofilm reaching the cells [5].

Conclusion

This review tried to compactly bandy the significance and operation of nanomedicine technology in opinion, treatment and forestallment of mortal ails especially some respiratory conditions.

Conflict of Interest

None.

References

1. Dames, Petra, Bernhard Gleich, Kerstin Hajek and Dietmar Eberbeck, et al. "Targeted delivery of magnetic aerosol droplets to the lung." Nat Nanotechnol 2 (2007): 495-499.

Google Scholar, Indexed at, Crossref

2. Kumar, Mukesh, Xiaoyuan Kong, Richard F. Lockey, and Shyam S. Mohapatra, et al. "Chitosan IFN-γ-pDNA nanoparticle (CIN) therapy for allergic asthma." Genetic Vaccines Ther 1 (2003): 1-10.

Google Scholar, Indexed at, Crossref

3. Kong, Xiaoyuan, Gary R. Hellermann, Weidong Zhang and Shyam S. Mohapatra. "Chitosan interferon-γ nanogene therapy for lung disease: Modulation of T-cell and dendritic cell immune responses." AACI 4 (2008): 1-11.

Google Scholar, Indexed at, Crossref

4. Pandey, Rajesh, Anjali Sharma, G. K. Khuller and Basudeo Prasad, et al. "Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis." J Antimicrob Chemother 52 (2003): 981-986.

Google Scholar, Indexed at, Crossref

5. Zarogoulidis, Paul, Eugene P. Goldberg, Nikos Karamanos and Konstantinos Zarogoulidis, et al. "Inhaled chemotherapy in lung cancer: Future concept of nanomedicine." Int J Nanomed 7 (2012): 1551.

Google Scholar, Indexed at, Crossref